Drugs / GEN-1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01489371 | Jul 2012 → Dec 2014 | fallopian tube carcinoma, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma +3 | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01118052 | Nov 2010 → Jul 2016 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | Gynecologic Oncology Group | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01118052 ↗ |
| Modality | Other / unclassified | “PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1” NCT01489371 ↗ |